Hairy cell leukemia is a mature B cell neoplasm. It is usually classified as a sub-type of chronic lymphoid leukemia for convenience. It is uncommon, representing about 2% of all leukemias, or less than a total of 2000 new cases diagnosed each year in North America and Western Europe combined.
Originally known as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s, this disease was formally named leukemic reticuloendotheliosis and its characterization significantly advanced by Bertha Bouroncle, M.D. and her colleagues at the Ohio State University College of Medicine in 1958. Its common name, which was coined in 1966, is derived from the appearance of the cells under a microscope.
When not further specified, the "classic" form is often implied. However, two variants have been described: Hairy cell leukemia-variant, which usually is diagnosed in men and a Japanese variant. The non-Japanese variant is more difficult to treat than either 'classic' HCL or the Japanese variant HCL.
This disease is rare, with fewer than 1 in 10,000 people being diagnosed with HCL during their lives. Men are four to five times more likely to develop hairy cell leukemia than women. In the United States, the annual incidence is approximately 3 cases per 1,000,000 men each year, and 0.6 cases per 1,000,000 women each year. It is less common in people of African and Asian descent compared to people of European descent.
It does not appear to be hereditary, although occasional familial cases that suggest a predisposition have been reported, usually showing a common HLA type.
Hairy cell leukemia-variant
Hairy cell leukemia-variant, or HCL-V, is usually described as a prolymphocytic variant of hairy cell leukemia. It was first formally described in 1980 by a paper from the University of Cambridge's Hayhoe lab. About 10% of HCL patients have this variant form of the disease, representing about 60-75 new HCL-V patients each year in the U.S. While classic HCL primarily affects men, HCL-V is somewhat more evenly divided between males and females. While the disease can appear at any age, the median age at diagnosis is over 70.
Similar to B-PLL in Chronic Lymphocytic Leukemia, HCL-V is a more aggressive disease. It is less likely to be treated successfully than classic HCL and remissions tend to be shorter. Many treatment approaches, such as Interferon-alpha, CHOP and common alkylating agents like cyclophosphamide provide very little benefit.) to interfere with bone marrow biopsies; and
- Low or no expression of CD25 (also called the Interleukin-2 receptor alpha chain or p55) on cell surfaces.
The lack of CD25, which is part of the receptor for a key immunoregulating hormone, may explain why HCL-V cases are normally resistant to treatment by immune system hormones.
HCL-V, which has a high proportion of hairy cells without a functional p53 tumor suppressor gene, is somewhat more likely to transform into a higher-grade disease, with Daniel Catovsky suggesting a typical transformation rate of 5% in the U.K., which is similar to the Richter's transformation rate for SLVL and CLL Among HCL-V patients, the most aggressive cases normally have the least amount of p53 gene activity. Hairy cells without the p53 gene tend, over time, to displace the less aggressive p53+ hairy cells.
Hairy cell leukemia-Japanese variant
Hairy cell leukemia-Japanese variant or HCL-J. There is also a Japanese variant, which is more easily treated. Treatment with cladribine has been reported.
This article is licensed under the Creative Commons Attribution-ShareAlike License.
It uses material from the Wikipedia article on
"Hairy cell leukemia"
All material adapted used from Wikipedia is available under the terms of the
Creative Commons Attribution-ShareAlike License.
Wikipedia® itself is a registered trademark of the Wikimedia Foundation, Inc.